Cathy Kelly
Senior Writer

Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
Annuity Payment Model For Cures May Get Test Drive In Massachusetts
First-ever implementation of often-discussed reimbursement approach for high-cost drugs would involve group of commercial payers to address “portability” issue and may start with Novartis’ Zolgensma.
Medicare Coverage For CAR-T Will Require Additional Patient Data Collection
National coverage decision does not limit Medicare payments to labeled indications or site of care. CMS expects to “leverage” existing FDA post-market data collection requirements but seeks additional data on patient-reported outcomes in some cases.
Pricing Cures For Sickle Cell Disease: Sen. Cassidy Weighs In
Price decisions based on straight calculation of medical costs avoided may overestimate value of a cure, Cassidy warns.
FDA's Real World Study On Adoption Of PD-1 Dosing Change Aims To Inform Reviewers
Study using US FDA’s Information Exchange and Data Transformation (INFORMED) program will focus on shift from weight-based to flat dosing for Opdivo and Keytruda.
Invitation Accepted: Biopharma Leaders Will Testify At Senate Hearing On Pricing
In addition to fielding tough questions about pricing practices at the session, executives may announce new voluntary efforts to lower drug costs and will offer their own ideas for legislation.
The Rebate Effect: ‘Traditional’ Brand Costs Decline 6.5% In Commercial Plans
Lower net costs held overall spending on retail prescription drugs in employer-sponsored insurance to an increase of just 0.4% in 2018, according to the latest Express Scripts Drug Trend Report.